#import "../../template.typ": project

#show: project.with(
  title: "Mechanism of Action: RARs",
  doc_id: "11.02",
)

Retinoids exert their biological effects by binding to specific nuclear receptors. These receptors act as transcription factors, regulating the expression of genes involved in cell growth, differentiation, and apoptosis.

== Retinoic Acid Receptors (RARs)

There are three primary subtypes of RARs located in the skin:

- *RAR-alpha (RARα):* Distributed throughout the epidermis and dermis.
- *RAR-beta (RARβ):* Found primarily in the dermis.
- *RAR-gamma (RARγ):* The most abundant subtype in the epidermis (approx. 90% of RARs in human skin).

== Receptor Selectivity of Common Retinoids

#table(
  columns: (1fr, 1fr, 1.5fr),
  inset: 10pt,
  align: horizon,
  [*Retinoid*], [*Receptor Affinity*], [*Clinical Focus*],
  [Tretinoin], [Pan-agonist (α, β, γ)], [General anti-aging, acne],
  [Adapalene], [Selective (β, γ)], [Acne, comedolysis],
  [Tazarotene], [Selective (β, γ)], [Psoriasis, Hyperpigmentation],
  [Trifarotene], [Highly Selective (γ)], [Acne, Truncal acne]
)

== Selectivity vs. Irritation

A common misconception is that *higher selectivity* automatically equates to *lower irritation*. However, clinical evidence challenges this:
- *Adapalene* (Selective $beta, gamma$) is generally *less* irritating than Tretinoin (Pan-agonist), fitting the theory.
- *Tazarotene* (Selective $beta, gamma$) is often observed to be *more* irritating than Tretinoin, contradicting the theory.
- *Trifarotene* (Highly Selective $gamma$) appears less irritating, but is used at a much lower concentration ($0.005\%$).

This suggests that irritation is likely linked to the mechanism of action itself (RAR-$gamma$ activation) and formulation factors, rather than just "off-target" effects on other receptors.

== Association with Hyperpigmentation

Both *RARα* and *RARγ* are significantly associated with the treatment of hyperpigmentation:

1. *Cell Turnover:* RAR activation stimulates keratinocyte proliferation, accelerating the "shedding" of melanin-containing cells.
2. *Melanogenesis Inhibition:* Retinoids can interfere with the transfer of melanosomes to keratinocytes and inhibit tyrosinase activity.
3. *RARγ Dominance:* Since RARγ is the predominant receptor in the epidermis where most pigment resides, selective agonists are particularly effective.

== Molecular Markers of Efficacy

Evidence that retinol is working at the cellular level includes:
- *Increased Collagen:* Stimulation of procollagen and inhibition of collagen-degrading MMPs (Matrix Metalloproteinases).
- *CRABP-II Induction:* Increased levels of Cellular Retinoic Acid Binding Protein-II.
- *Hyaluronan Production:* Induction of HAS (Hyaluronan Synthase) genes.
- *Epidermal Thickening:* Also known as hyperplasia.

== The EGF Pathway & "Retinization"

RAR activation triggers the *Epidermal Growth Factor (EGF)* pathway. This leads to:
- Rapid cell production in the top layers of the skin.
- *Hyperplasia:* The clinical "peeling" or "retinoid dermatitis" (retinization) often observed when starting retinoids. This is a unique side effect linked directly to the retinoid mechanism.
